Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of IPF according to the International Consensus Statement~* Bronchoalveolar lavage (BAL) showing no features to support an alternative diagnosis.~* Patients in whom it was possible to determine single breath DLco.~* Patients with newly or previously diagnosed IPF, in whom it was clinically justified to use the standardised regimen azathioprine plus prednisone~Exclusion Criteria:~* Known intolerance to N-Acetylcysteine.~* Patients with respiratory infections at study entry should be excluded until the infections have been treated successfully (VC and Dlco comparable with the values before the infection).~* Patients with pre-existing disease that interferes with the evaluation of IPF: extensive old TBC lesions, significant bronchiectasis, moderate or severe COPD.~* Patients with malignancy in the last 5 years. If the patient had a malignancy in the past and is free of malignancy for more than five years, the patient is regarded as healed.~* Patients with heart failure.~* Patients with hepatic function abnormalities contraindicating the use of azathioprine (i.e. clinically significant abnormalities of PTT and/or GGT).~* Patients with a renal clearance \< 10ml/min and/or hematuria and/or proteinuria of collagen vascular disease origin. A renal clearance is only performed in the presence of an abnormal serum creatinine and/or serum urea level.~* Patients who are artificially ventilated.~* Prednisone at a dose \> 0.5 mg/kg/day (or other glucocorticoids such as triamcinolone, dexamethasone or methylprednisolone at an equivalent dose) or azathioprine at a dose \> 2 mg/kg/day during the last month prior to inclusion.~* Use of other immunosuppressives (such as cyclophosphamide and colchicine) is not allowed in the last month and for the duration of the trial.~* Any form of anticancer therapy or methotrexate are not allowed when used for more than 1 week in the past and for the duration of the trial.~* Amiodarone or nitrofurantoin are not allowed in the last 5 years, when used for more than 1 week in the past and for the duration of the trial.~* Allopurinol, oxypurinol, thiopurinol, anti-oxidants (e.g. vitamin E) or glutathione supplements are not allowed in the last month and during the trial.~* The use of interferon or other antifibrotics (e.g. pirfenidone) is not allowed in the past and during the study.~* The use of NAC therapy at a dosage of more than 600 mg/day is not allowed in the last 3 years for a total period of more than 3 months.~* Patients suffering or having suffered from documented active ulcer within the last 3 years.~* Patients in whom the standardised treatment regimen is contraindicated or not justified.~* Pregnancy.~* Known or suspected drug or alcohol abuse.~* Patients on other investigational compounds or participating in clinical trials on investigational compounds within the last 3 months.~* Patients expected to be non-compliant in taking the medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): patients taking NAC 600 mg t.i.d.
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).